Wearable tech puts hormone health to the test

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Diagnosis or suspected diagnosis of at least one endocrine or metabolic disorder, including: * Overweight or obesity, defined as body mass index of 25 kg/m² or higher * Essential hypertension * Diabetes mellitus, including type 1 diabetes, type 2 diabetes, gestational diabetes, maturity-onset diabetes of the young, or unclassified diabetes * Hypoglycemia * Endogenous hypercortisolism * Primary aldosteronism * Endogenous or exogenous adrenal insufficiency * Congenital adrenal hyperplasia * Polycystic ovary syndrome * Adrenocortical tumor or adrenal incidentaloma * Functional or non-functional pituitary tumor * Pituitary insufficiency * Polyuria-polydipsia syndrome * Hyponatremia * Functional or non-functional neuroendocrine tumor * Osteoporosis * Lipid disorder * Thyroid disorder * Hypoparathyroidism or hyperparathyroidism * Inborn error of metabolism * People undergoing gender-affirming hormone therapy Exclusion Criteria: * Known or suspected severe skin disorder or allergy that may interfere with wearable sensor placement, such as extensive eczema, psoriasis, chronic ulcers, or severe tape intolerance * Known impaired wound healing or strong keloid tendency that would make repeated skin application or microneedle use unsuitable * Pregnancy or lactation, for participation in home monitoring or dynamic hormone sampling * Known or suspected bleeding disorder, such as von Willebrand disease * Current treatment with anticoagulant or antiplatelet therapy at a dose that increases bleeding risk * Severe acute or chronic medical condition that, in the investigator's opinion, would interfere with study procedures or compromise participant safety, such as decompensated heart failure, unstable angina, or acute systemic infection * Current lithium treatment, because the intervention may alter lithium levels * Recent travel across more than 4 time zones within the past 14 days, if study endpoints rely on circadian hormone profiles * Ongoing shift work, if study endpoints rely on circadian hormone profiles * Inability to give informed consent * Inability to comply with study procedures